The significance of atherogenic indices in patients on hemodialysis

American Journal of Nephrology

Volumn 20, Issue 2, 2000, Pages 107-115

  Oishi, Kazuhiro ^a   Nagake, Yoshio ^a   Yamasaki, Hiroko ^a   Fukuda, Shinji ^a   Ichikawa, Haruo ^a   Ota, Kosuke ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Ankle arm blood pressure index; Atherosclerosis; Cholesterol; Hemodialysis; Homocysteine cardiac troponin T; Lipoprotein(a); Remnant like particles

Indexed keywords

CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; TROPONIN T;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD LEVEL; BLOOD PRESSURE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEVICE; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR;

EID: 0034006086     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000013566     Document Type: Article

References (55)

1. Japanese Society for Dialysis Therapy: An overview of regular dialysis treatment in Japan (as of December 31, 1997). J Jpn Soc Dial Thcr 1999;32:1-17.
2. Fishbane S, Youn S, Kowalski EJ, Frei GL: Ankle-arm blood pressure index as a marker for atherosclerotic vascular diseases in hemodialysis patients. Am J Kidney Dis 1995;25:34-39.
3. Abe A, Noma A: Enzyme-linked immunosorbent assay of lipoprotein(a) in serum and cord blood. Clin Chim Acta 1998;177:31-40.
4. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ: Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti-apo B-100 and anti-apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993;223:53-71.
5. Araki A, Sako Y: Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422: 43-52.
6. Katus HA, Looser S, Hallermayer K, Remppis A, Scheffold T, Borgya A, Essig U, Geus U: Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin Chim 1992;38:389-393.
7. Shinzato T, Nakai S, Fujiwara Y, Takai I, Morita H, Nakane K, Maeda K: Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentration. Nephron 1994;67:280-290.
8. Shinzato T, Nakai S, Miwa M, Iwayama N, Takai I, Matsumoto Y, Morita H, Maeda K: New method to calculate creatinine generation rate using pre- and postdialysis creatinine concentrations. Artif Organs 1997;21:864-872.
9. Kannel WB, McGee DL: Diabetes and cardiovascular disease, The Framingham Study. JAMA 1979;241:2035-2038.
10. Kronenberg F, Utermann G, Dieplinger H: Lp(a) in renal disease. Am J Kidney Dis 1996; 27:1-25.
11. Krempler F, Kostner G, Bolzano K, Sandhofer F: Turnover of lipoprotein(a) in man. J Clin Invest 1980;65:1483-1490.
12. Greiber S, Wanner G: Lipoprotein(a) in nephrotic syndrome and end-stage renal disease. Miner Electrolyte Metab 1997;23:161-165.
13. Stenvinkel P, Berglund L: Lipoprotein(a) in chronic renal disease. Miner Electrolyte Metab 1996;22:16-21.
14. Hirata K, Kikuchi S, Saku K, Jimi S, Zhang B, Naito S, Yamaguchi H, Arakawa K: Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int 1993;44:1062-1070.
15. Elisaf M, Siamopoulos KC: Are the increased Lp(a) levels in hemodialysis patients related to glucose intolerance and hemodialysis duration? Nephron 1996;74:623-624.
16. Kronenberg F, König P, Nyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995;6:110-120.
17. Okura Y, Saku K, Hirata K, Zhang B, Liu R, Ogahara S, Naito S, Kajiyama G, Arakawa K: Serum Lp(a) levels in maintenance hemodialysis patients. Nephron 1993;65:46-50.
18. Hong SY, Yang DH: Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome. Nephron 1995;65:125-130.
19. Nakagawa H, Kida Y, Sakamoto K, Haneda M, Kikkawa R: Relationship between the stage of diabetic nephropathy and serum lipoprotein(a) concentrations - Influence of hypoproteinemia (in Japanese). Jpn J Nephrol 1996;38: 513-518.
20. Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Grochenig E, Utermann G, Dieplinger H: Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 1994;14:1404-1411.
21. Hernandez E, Praga M, Alamo C, Araque A, Morales JM, Alcazar JM, Ruilope LM, Rodicio JL: Lipoprotein(a) and vascular access survival in patients on chronic hemodialysis. Nephron 1996;72:145-149.
22. Docci D, Manzoni G, Bilancioni R, Delvecchio C, Capponcini C, Baldrati L, Neri L, Feletti C: Serum lipoprotein(a) and coronary artery disease in uremic patients on chronic hemodialysis. Int J Artif Organs 1994;17:41-45.
23. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475-482.
24. Gault MH, Longerich LL, Purchase L, Harnett J, Breckeriridge C: Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 1995;70:155-170.
25. Leu JG, Liou HH, Wu SC, Yang WC, Huang TP, Wu SC: Low molecular weight heparin in diabetic and nondiabetic hypercholesterolemic patients receiving long-term hemodialysis. J Formos Med Assoc 1998;97:49-54.
26. Nakamura N, Hamazaki T, Kobayashi M, Ohta M, Okuda K: Effects of eicosapentaenoic acids on remnant-like particles cholesterol concentrations and plasma fatty acid composition in patients with diabetes mellitus. In Vivo 1998;12:311-314.
27. Soutar AK: Lipoprotein-remnant receptors -Second receptor verified? Nature 1989;341: 106-107.
28. Nestel PJ, Fidge NH, Tan MH: Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 1982;307:329.
29. Oda H, Yorioka N, Okushin S, Nishida Y, Kushihata S, Ito T, Yamakido M: Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis. Nephron 1997;76:7-14.
30. Sakata K, Miho N, Shirotani M, Yoshida H, Takada Y, Takada A: Remnant-like particle cholesterol is a major risk factor for myocardial infarction in vasospastic angina with nearly normal coronary artery. Atherosclerosis 1998; 136:225-231.
31. Loehrer FMT, Angst CP, Brunner FP, Haefeli WE, Fowler B: Evidence for disturbed S-adenosylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure: A cause for disturbed methylation reactions? Nephrol Dial Transplant 1998;13:656-661.
32. Hirose S, Kim S, Matsuda A, Itakura Y, Matsumura O, Tamura H, Nagasawa R, Mitarai T, Isoda K: Effect of folic acid supplementation on hyperhomocysteinemia in CAPD patients: Effects on unsaturated fatty acids (in Japanese). Jpn J Nephrol 1998;40:8-16.
33. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J, Rosenberg IH: Folate status is the major determinant of fasting total homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996;123:193-202.
34. Hirose S, Kim S, Matsuda A, Itakura Y, Mitarai T, Isoda K: Hyperhomocysteinemia in patients on dialysis, as determined by the methionine loading test. J Jpn Soc Dial Ther 1997;30: 967-973.
35. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230-234.
36. Perna AF, Santo NG, Ingrosso D: Adverse effect of hyperhomocysteinemia and their management by folic acid. Miner Electrolyte Metab 1997;23:174-178.
37. Janssen MJFM, Guldener C, Jong GMT, Berg M, Donker AJM: Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 1996;22:110-114.
38. Wilcken DEL, Gupta VJ, Reddy SG: Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin Sci 1980;58: 427-430.
39. Nakazono H, Nagake Y, Kumagai I, Ichikawa H, Suga H, Makino H: Relationship between parameters of the urea kinetic model and serum amino acid levels in patients on hemodialysis. Clin Exp Nephrol 1999;3:116-122.
40. Mohamed ES, Bjorn A, Jonas B: Evidence of taurine depletion and accumulation of cystine sulfinic acid in chronic dialysis patients. Kidney Int 1996;50:1713-1717.
41. Guttormsen AB, Ueland PM. Svarstad E, Refsum H: Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997;52:495-502.
42. Vincent W, Robinson D, Robinson K: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 1996;50:11-17.
43. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;94: 2743-2748.
44. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacquens PF, Selhub J, Dworkin L, Rosenberg IH: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients (a prospective study). Arterioscler Thromb Vasc Biol 1997;17:2554-2558.
45. Masser PA, Talyor LM, Porter JM: Importance of elevated plasma homocysteine levels as a risk factor for atherosclerosis. Ann Thorac Surg 1994;58:1240-1246.
46. Frankel WL, Herold DA, Ziegler TW, Fitzgerald RL: Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure. Am J Clin Pathol 1996;106:118-123.
47. Akagi M, Nagake Y, Ichikawa H, Makino H, Ota Z: Myocardial troponin T levels in patients with diabetic nephropathy. Jpn J Nephrol 1996;38:136-140.
48. Akagi M, Nagake Y, Makino H, Shikata K, Ota Z: A comparative study of myocardial troponin T levels in patients undergoing hemodialysis. Jpn J Nephrol 1995;37:639-643.
49. Kobayashi S, Tanaka M, Tamura N, Hashimoto H, Hirose S: Serum cardiac troponin T in polymyositis/dermatomyositis. Lancet 1992; 340:726.
50. Gerhardt W, Ljungdahl L: Troponin T: A sensitive and specific diagnostic and prognostic marker of myocardial damage. Clin Chim Acta 1998;272:47-57.
51. Bodor GS, Porterfield D, Voss E, Kelly J, Smith S, Apple FS: Cardiac troponin T composition in normal and regenerating human skeletal muscle (abstract). Clin Chem 1995;41: S148.
52. Saggin L, Gorza L, Ausoni S, Schiaffino S: Cardiac troponin T in developing, regenerating, and denervated rat skeletal muscle. Development 1990;110:547-554.
53. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB: Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993;270:465-469.
54. Newman AB, Sutton-Tyrrel K, Vogt MT, Kuller LH: Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 1993;270:487-489.
55. Kondo H, Teramoto Y, Mitsuiki K, Tsuruya K, Harada A: Evaluation of ankle-arm blood pressure index (AABI) as a marker of arteriosclerosis in hemodialysis patients. J Jpn Soc Dial Ther 1997;30:1123-1127.